• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
March 11, 2025 01:39 PM EDTUpdated 04:22 PM
Pharma
Law

Mer­ck scores a win in Gar­dasil cas­es af­ter judge says plain­tiffs’ ev­i­dence ‘falls far short’

Nicole DeFeudis

Editor

Mer­ck con­vinced a fed­er­al judge to toss claims al­leg­ing that it failed to prop­er­ly warn pa­tients of po­ten­tial risks re­lat­ed to its Gar­dasil HPV vac­cine …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • WHO adds Gilead­'s twice-year­ly in­jec­tion to glob­al PrEP guide­lines July 14, 2025
  • Mer­ck sends new month­ly oral PrEP to Phase 3 af­ter ear­li­er is­la­travir set­back July 14, 2025
  • Up­dat­ed: GSK's Vi­iV ex­pands li­cens­ing pact to in­clude long-act­ing HIV treat­ment July 14, 2025
TRENDING NOW

Af­ter Phase 3 obe­si­ty suc­cess, Hen­grui plans Chi­na ap­proval fil­ing for Kail­era-part­nered drug

FDA em­ploy­ees let go in April re­ceive fi­nal ter­mi­na­tion no­tices

FDA chief calls for low­er user fees as ne­go­ti­a­tions be­gin for eighth round of PDU­FA

Af­ter long saga, 23and­Me's deal with Anne Wo­j­ci­ck­i's non­prof­it fi­nal­ly clos­es

As­traZeneca posts a piv­otal tri­al win for blood pres­sure pill be­hind $1.3B deal

Judge re­jects Ab­b­Vie’s fight against Mis­souri 340B con­tract phar­ma­cy law

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times